Skip to main content
. 2020 Mar 13;78(1):249–270. doi: 10.1007/s00018-020-03491-1

Fig. 4.

Fig. 4

AZD2014 attenuate eIF4E phosphorylation in TSC2+/− mice. a Tsc2+/− mice at the age of 12 months were treated for two months with either AZD2014 or rapamycin, or with vehicle control. Lysates prepared from tissues from the mice were analysed by Western blot for phosphorylation of rpS6 at Ser235/Ser236 and eIF4E at Ser209. Actin was used as a loading control. Representative blots are shown. b Quantification of A (kidney, P-eIF4E Ser209). c Quantification of a (liver, P-eIF4E Ser209). d Quantification of a (kidney, P-rpS6 Ser235/Ser236). e Quantification of a (liver, P-rpS6 Ser235/Ser236). f Paraffin sections of kidney prepared from the drug-treated Tsc2+/− mice were analysed by immunohistochemistry. Representative IHC-stained images show phosphorylation of rpS6 at Ser235/Ser236, PKB/Akt at S473 and eIF4E at Ser209. Black arrows point to stained cells as shown in the boxed areas. Black lines are scale bars. c cystic lesions; KM, kidney medulla. For panels b–e, results are presented as means ± SD, n = 3. *0.01 ≤ P < 0.05; **0.001 ≤ P < 0.01; ***P < 0.001 (one-way ANOVA); $P < 0.001 (two-way ANOVA)